Single Vitamins Experience Growth of 166% Amid Coronavirus Pandemic
DUBLIN, April 29, 2020 /PRNewswire/ -- ResearchAndMarkets.com published a new article on the pharmaceuticals industry, "Single Vitamins Experience Growth of 166% Amid Coronavirus Pandemic"
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
With the outbreak of COVID-19, sales of high dose vitamin C supplements have soared. Vitamin C has long been seen as important for the immune system and many consumers are looking to give their immunity a boost at this time. The lockdown has also created huge demand for vitamin D supplements.
This vitamin is typically absorbed from sunlight and as the public have been encouraged to spend more time indoors, some are worried about the effect on their vitamin D levels. Many consumers are turning to supplements as a result. Sales of children's single and multivitamins are also growing rapidly as consumers try to protect their families from the effects of COVID-19. Companies like Pharmavite, Pfizer, Bayer and Santa Cruz Nutritionals have seen increased demand for their vitamin supplements.
To see the full article and a list of related reports on the market, visit "Single Vitamins Experience Growth of 166% Amid Coronavirus Pandemic"
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/single-vitamins-experience-growth-of-166-amid-coronavirus-pandemic-301049268.html
SOURCE Research and Markets
